Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail aims to extend life in tough lung cancer

NCT ID NCT06422143

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 04, 2026 · Updated 13 times

Summary

This Phase 3 trial tests whether adding a maintenance drug (sacituzumab tirumotecan) after initial chemo-immunotherapy improves survival in people with metastatic squamous non-small cell lung cancer. About 851 participants will receive pembrolizumab plus chemotherapy, then either continue pembrolizumab alone or add the experimental drug. The goal is to see if the combination helps people live longer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pembrolizumab (Keytruda) and sacituzumab tirumotecan (sac-TMT)
What this could lead to
If successful, this could offer a new first-line treatment option that extends survival for people with advanced squamous lung cancer.
What could go wrong
This is a large Phase 3 trial, but the experimental maintenance drug may not improve survival over standard care. Side effects from the combination could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 851 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2024

Expected to finish

Aug 2031

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of squamous non-small cell lung cancer (NSCLC) \[Stage IV: M1a, M1b, M1c, American Joint Committee on Cancer Staging Manual, version 8\] * Measurable disease per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 as assessed by the local site investigator/radiology * Has life expectancy ≥3 months * Has Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1 assessed within 7 days prior to allocation * Archival tumor tissue sample or newly obtained core, incisional, or excisional biopsy of a tumor lesion not previously irradiated has been provided * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART) * Participants who are hepatitis B surface antigen (HBsAg)-positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load before allocation * Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening * Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to Grade ≤1 or baseline (participants with endocrine-related AEs who are adequately treated with hormone replacement are eligible) * Has adequate organ function * For Maintenance only (prior to randomization): is without disease progression of their NSCLC, as determined by BICR using RECIST 1.1 after completion of study-specified Induction with an evaluable scan at Week 12 or most recent scan before randomization * For Maintenance only (prior to randomization): has ECOG PS of 0 or 1 as assessed at the Prerandomization Visit * For Maintenance only (prior to randomization): all AEs (with the exception of alopecia, Grade ≤2 fatigue, Grade ≤2 peripheral neuropathy, and Grade ≤2 endocrine-related AEs requiring treatment or hormone replacement) have recovered * For Maintenance only (prior to randomization): has not experienced a pneumonitis/interstitial lung disease (ILD) event during the study-specified induction Exclusion Criteria: * Diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements * History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing * Active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea) * Has uncontrolled, significant cardiovascular disease or cerebrovascular disease including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of QTcF interval to \>480 ms, and other serious cardiovascular and cerebrovascular diseases within 6 months before study intervention * HIV-infected participants who have been newly diagnosed or with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * Received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their metastatic NSCLC. Note: Prior treatment with chemotherapy and/or radiation as a part of neoadjuvant or adjuvant therapy or chemoradiation therapy for nonmetastatic NSCLC is allowed as long as therapy was completed at least 12 months before diagnosis of metastatic NSCLC * Received prior therapy with an anti-programmed cell death 1 protein (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti programmed cell death ligand 2 (PD-L2) agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, cytotoxic T lymphocyte-associated protein 4, OX-40, CD137). Note: Prior treatment with an anti-PD-1 or anti-PD-L1 agent for nonmetastatic NSCLC is allowed as long as therapy was completed at least 12 months before diagnosis of metastatic NSCLC * Received prior treatment with a trophoblast cell-surface antigen 2 (TROP2)-targeted antidrug conjugate (ADC) * Received radiation therapy to the lung that is \>30 Gray within 6 months of start of study intervention * Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids * Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention * Participants who have not adequately recovered from major surgery or have ongoing surgical complications * Received prior treatment with a topoisomerase I inhibitor-containing ADC * Is currently receiving a strong inducer/inhibitor of CYP3A4 that cannot be discontinued for the duration of the study (the required washout period before starting sac-TMT is 2 weeks) * Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. * Has known central nervous system (CNS) metastases/carcinomatous meningitis * Severe hypersensitivity (≥Grade 3) to study intervention and/or any of its excipients or to another biologic therapy * Active autoimmune disease that has required systemic treatment in the past 2 years (replacement therapy \[eg, thyroxine, insulin, or physiologic corticosteroid\] is allowed) * Has a history of (noninfectious)pneumonitis/ILD that required steroids, has current pneumonitis/ILD, or has suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments at Screening * Active infection requiring systemic therapy * History of allogeneic tissue/solid organ transplant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic squamous non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma non-small cell squamous lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer NSCLC

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    172 sites in 24 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Aichi Cancer Center ( Site 2502)

    RECRUITING

    Nagoya, Aichi-ken, 464-8681, Japan

  • Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0146)

    RECRUITING

    Minneapolis, Minnesota, 55407, United States

  • Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 1800)

    RECRUITING

    Ankara, 06800, Turkey (Türkiye)

  • Army Medical Center of People's Liberation Army-respiratory ( Site 2426)

    ACTIVE_NOT_RECRUITING

    Chongqing, Chongqing Municipality, 400042, China

  • Asan Medical Center ( Site 2105)

    RECRUITING

    Seoul, 05505, South Korea

  • Azienda Ospedaliera Maggiore della Carita ( Site 1416)

    RECRUITING

    Novara, 28100, Italy

  • Azienda Ospedaliera S. Giovanni Addolorata-Oncologia Medica ( Site 1409)

    RECRUITING

    Rome, Lazio, 00184, Italy

  • Azienda Ospedaliera Spedali Civili di Brescia-Oncology ( Site 1414)

    RECRUITING

    Brescia, 25123, Italy

  • Bacs-Kiskun Varmegyei Oktatokorhaz ( Site 1100)

    RECRUITING

    Kecskemét, Bács-Kiskun county, 6000, Hungary

  • Bangkok Metropolitan Administration Medical College and Vajira Hospital ( Site 2300)

    RECRUITING

    Dusit, Bangkok, 10300, Thailand

  • Beijing Cancer Hospital ( Site 2411)

    ACTIVE_NOT_RECRUITING

    Beijing, Beijing Municipality, 100142, China

  • Beijing Cancer hospital-intrathoratic deparmtment II ( Site 2410)

    ACTIVE_NOT_RECRUITING

    Beijing, Beijing Municipality, 100142, China

  • Bialostockie Centrum Onkologii ( Site 1520)

    RECRUITING

    Bialystok, Podlaskie Voivodeship, 15-027, Poland

  • Bradford Hill Norte ( Site 0420)

    RECRUITING

    Antofagasta, 1240000, Chile

  • Bradfordhill-Clinical Area ( Site 0407)

    RECRUITING

    Santiago, Region M. de Santiago, 8420383, Chile

  • Burjeel Medical City ( Site 2600)

    COMPLETED

    Abu Dhabi, Abu Dhabi Emirate, 92510, United Arab Emirates

  • CARTI Cancer Center ( Site 0006)

    RECRUITING

    Little Rock, Arkansas, 72205, United States

  • CHD Vendee ( Site 0901)

    RECRUITING

    La Roche-sur-Yon, Vendee, 85000, France

  • CHUS - Hospital Clinico Universitario-Servicio de Oncologia ( Site 1703)

    RECRUITING

    Santiago de Compostela, Galicia, 15706, Spain

  • Cabinet Medical Oncomed ( Site 2005)

    RECRUITING

    Timișoara, Timiș County, 300239, Romania

  • Cancer Institute Hospital of JFCR ( Site 2500)

    RECRUITING

    Koto, Tokyo, 135-8550, Japan

  • Capital Health Medical Center - Hopewell ( Site 0034)

    RECRUITING

    Pennington, New Jersey, 08534, United States

  • Cardiomed SRL Cluj-Napoca ( Site 2002)

    RECRUITING

    Cluj-Napoca, Cluj, 400015, Romania

  • Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-centre-du-quebec ( Site 0106)

    RECRUITING

    Trois-Rivières, Quebec, G8Z 3R9, Canada

  • Centricity Research Columbus Cancer Center ( Site 0111)

    COMPLETED

    Columbus, Georgia, 31904, United States

  • Centro Cancerológico del Caribe (CECAC) ( Site 0509)

    RECRUITING

    Barranquilla, Atlántico, 080002, Colombia

  • Centro Ricerche Cliniche di Verona s.r.l. c/o Policlinico G.B.Rossi ( Site 1415)

    RECRUITING

    Verona, 37134, Italy

  • Centro de Investigación del Maule ( Site 0419)

    COMPLETED

    Talca, Maule Region, 3481349, Chile

  • Centrul Medical Medicover Victoria ( Site 2000)

    RECRUITING

    Bucharest, Bucharest, 010626, Romania

  • Centrul de Oncologie Sfantul Nectarie-Medical ( Site 2004)

    RECRUITING

    Craiova, Dolj, 200542, Romania

  • Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 1503)

    RECRUITING

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-796, Poland

  • Chang Gung Medical Foundation-Linkou Branch-Clinic of Chest Medicine ( Site 2202)

    RECRUITING

    Taoyuan, 333, Taiwan

  • Chang Gung Memorial Hospital at Kaohsiung ( Site 2207)

    RECRUITING

    Kaohsiung City, 83301, Taiwan

  • Charité Campus Virchow-Klinikum-Department of Infectious Diseases and Pulmonary Medicine ( Site 1003)

    RECRUITING

    Berlin, 13353, Germany

  • Chiba University Hospital ( Site 2517)

    RECRUITING

    Chiba, 260-8677, Japan

  • Chungnam national university hospital-Department of Internal Medicine ( Site 2107)

    RECRUITING

    Daejeon, Taejon-Kwangyokshi, 35015, South Korea

  • City Hospital, Nottingham University Hospitals NHS Trust-NCCTT ( Site 1911)

    RECRUITING

    Nottingham, Nottinghamshire, NG5 1PB, United Kingdom

  • Cleveland Clinic Abu Dhabi ( Site 2650)

    COMPLETED

    Abu Dhabi, Abu Dhabi Emirate, 112412, United Arab Emirates

  • Clinica Polisano ( Site 2008)

    RECRUITING

    Sibiu, 550253, Romania

  • Clinique Clairval ( Site 0904)

    RECRUITING

    Marseille, Bouches-du-Rhone, 13009, France

  • Clínica San Antonio ( Site 0606)

    RECRUITING

    Trujillo, La Libertad, 13008, Peru

  • Clínicas AUNA Sede Chiclayo ( Site 0604)

    ACTIVE_NOT_RECRUITING

    Chiclayo, Lambayeque, 14001, Peru

  • Dokkyo Medical University Hospital ( Site 2527)

    RECRUITING

    Shimotsuga-gun, Tochigi, 321-0293, Japan

  • Ehime University Hospital ( Site 2511)

    RECRUITING

    Tōon, Ehime, 791-0295, Japan

  • FALP ( Site 0409)

    RECRUITING

    Santiago, Region M. de Santiago, 7500921, Chile

  • FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0500)

    RECRUITING

    Bogotá, Bogota D.C., 110131, Colombia

  • Faculty of Medicine - Khon Kaen University ( Site 2305)

    RECRUITING

    Muang, Changwat Khon Kaen, 40002, Thailand

  • Faculty of Medicine Siriraj Hospital ( Site 2301)

    RECRUITING

    Bangkoknoi, Bangkok, 10700, Thailand

  • Fakultni nemocnice Olomouc-Klinika plicnich nemoci a tuberkulozy ( Site 0802)

    RECRUITING

    Olomouc, 779 00, Czechia

  • First Huai'an Hospital Affiliated to Nanjing Medical University ( Site 2402)

    ACTIVE_NOT_RECRUITING

    Huai'an, Jiangsu, 223300, China

  • Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1404)

    RECRUITING

    Milan, Lombardy, 20133, Italy

  • Fondazione IRCCS Policlinico San Matteo-Oncology ( Site 1410)

    RECRUITING

    Pavia, 27100, Italy

  • Fondazione IRCCS San Gerardo dei Tintori-Oncologia ( Site 1412)

    RECRUITING

    Monza, Lombardy, 20900, Italy

  • Fujian Provincial Cancer Hospital ( Site 2419)

    ACTIVE_NOT_RECRUITING

    Fuzhou, Fujian, 350014, China

  • Fujita Health University Hospital ( Site 2515)

    RECRUITING

    Toyoake, Aichi-ken, 470-1192, Japan

  • Fundacion Intecnus ( Site 0205)

    RECRUITING

    Bariloche, Río Negro Province, R8402APU, Argentina

  • Fundación Valle del Lili-Oncology CIC ( Site 0505)

    RECRUITING

    Cali, Valle del Cauca Department, 760032, Colombia

  • GEFOS Gesellschaft f. onkologische Studien ( Site 1005)

    RECRUITING

    Dortmund, North Rhine-Westphalia, 44309, Germany

  • Gazi Universitesi-Oncology ( Site 1804)

    RECRUITING

    Ankara, 06560, Turkey (Türkiye)

  • Gunma Prefectural Cancer Center ( Site 2510)

    RECRUITING

    Ōta, Gunma, 373-8550, Japan

  • Hacettepe Universite Hastaneleri-oncology hospital ( Site 1801)

    RECRUITING

    Ankara, 06230, Turkey (Türkiye)

  • Harbin Medical University Cancer Hospital-oncology of department ( Site 2415)

    ACTIVE_NOT_RECRUITING

    Harbin, Heilongjiang, 150000, China

  • Henan Cancer Hospital-Pneumology department ( Site 2423)

    ACTIVE_NOT_RECRUITING

    Zhengzhou, Henan, 450008, China

  • Hirosaki University Hospital ( Site 2514)

    RECRUITING

    Hirosaki, Aomori, 036-8563, Japan

  • Hospital Aleman-Oncology ( Site 0202)

    RECRUITING

    Buenos Aires, C1118AAT, Argentina

  • Hospital Insular de Gran Canaria-Oncology ( Site 1701)

    RECRUITING

    Las Palmas de Gran Canaria, Las Palmas, 35016, Spain

  • Hospital Militar Central Coronel Luis Arias Schereiber ( Site 0602)

    RECRUITING

    Lima, 15076, Peru

  • Hospital Nossa Senhora da Conceição ( Site 0300)

    RECRUITING

    Porto Alegre, Rio Grande do Sul, 91350-200, Brazil

  • Hospital Paulistano ( Site 0307)

    RECRUITING

    São Paulo, 01321-001, Brazil

  • Hospital Quirón Málaga ( Site 1704)

    RECRUITING

    Málaga, Malaga, 29004, Spain

  • Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1700)

    RECRUITING

    Barcelona, 08035, Spain

  • Hospital Universitario Fundación Jiménez Díaz-Oncology & Hematology ( Site 1702)

    RECRUITING

    Madrid, 28040, Spain

  • Hospital Universitario Virgen de Valme-Departamento de Oncologia ( Site 1705)

    RECRUITING

    Seville, 41014, Spain

  • Hospital de Base de São José do Rio Preto ( Site 0310)

    RECRUITING

    São José do Rio Preto, São Paulo, 15090-000, Brazil

  • Hospital do Cancer de Pernambuco ( Site 0312)

    RECRUITING

    Recife, Pernambuco, 50040-000, Brazil

  • Hôpital Robert Schuman ( Site 0907)

    RECRUITING

    Vantoux, Lorraine, 57070, France

  • Hôpital Saint-Louis ( Site 0906)

    COMPLETED

    Paris, 75475, France

  • Institut de Cancérologie de l'Ouest ( Site 0908)

    RECRUITING

    Angers, Maine-et-Loire, 49055, France

  • Instituto Alexander Fleming ( Site 0203)

    RECRUITING

    Ciudad Autónoma de Buenos Aires, Buenos Aires, C1426ANZ, Argentina

  • Instituto Médico Río Cuarto ( Site 0204)

    RECRUITING

    Río Cuarto, Córdoba Province, X5800AEV, Argentina

  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 0200)

    RECRUITING

    Mar del Plata, Buenos Aires, B7600FZO, Argentina

  • Instituto de Oncologia Saint Gallen ( Site 0304)

    RECRUITING

    Santa Cruz do Sul, Rio Grande do Sul, 96830-180, Brazil

  • Instytut Gruzlicy i Chorob Pluc w Warszawie ( Site 1523)

    RECRUITING

    Warsaw, Masovian Voivodeship, 01-138, Poland

  • Intermountain Health Cancer Center Lutheran Hospital ( Site 0119)

    RECRUITING

    Golden, Colorado, 80401, United States

  • Intermountain Health St. Mary's Regional Hospital ( Site 0116)

    RECRUITING

    Grand Junction, Colorado, 81501, United States

  • Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 0311)

    RECRUITING

    Porto Alegre, Rio Grande do Sul, 90020-090, Brazil

  • Istituto Clinico Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1408)

    RECRUITING

    Rozzano, Milano, 20089, Italy

  • Istituto Nazionale Tumori IRCCS Fondazione Pascale-Oncologia clinica sperimentale Toraco-Polmonare ( Site 1401)

    RECRUITING

    Naples, Campania, 80131, Italy

  • Istituto Nazionale Tumori Regina Elena-Oncologia Medica 2 ( Site 1402)

    RECRUITING

    Rome, Roma, 00144, Italy

  • Izmir Atatürk Training and Research Hospital ( Site 1810)

    RECRUITING

    Izmir, 35360, Turkey (Türkiye)

  • Jilin Province Tumor Hospital-GCP office ( Site 2413)

    ACTIVE_NOT_RECRUITING

    Changchun, Jilin, 130000, China

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0035)

    RECRUITING

    Hackensack, New Jersey, 07601, United States

  • Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház-Onkologiai Kozpont ( Site 1103)

    RECRUITING

    Szolnok, Jász-Nagykun-Szolnok, 5004, Hungary

  • Kanagawa Cancer Center ( Site 2504)

    RECRUITING

    Yokohama, Kanagawa, 241-8515, Japan

  • Kanagawa Cardiovascular and Respiratory Center ( Site 2518)

    RECRUITING

    Yokohama, Kanagawa, 236-0051, Japan

  • Kanazawa University Hospital ( Site 2513)

    RECRUITING

    Kanazawa, Ishikawa-ken, 920-8641, Japan

  • Kansai Medical University Hospital ( Site 2503)

    RECRUITING

    Hirakata, Osaka, 573-1191, Japan

  • Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 0100)

    RECRUITING

    Kingston, Ontario, K7L 2V7, Canada

  • Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 0710)

    RECRUITING

    Vienna, 1210, Austria

  • Klinik Hietzing ( Site 0740)

    RECRUITING

    Vienna, 1130, Austria

  • Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung ( Site 1001)

    RECRUITING

    Essen, North Rhine-Westphalia, 45136, Germany

  • Kobe Minimally Invasive Cancer Center ( Site 2528)

    RECRUITING

    Kobe, Hyōgo, 650-0046, Japan

  • Kochi Medical School Hospital ( Site 2526)

    RECRUITING

    Nankoku, Kochi, 783-8505, Japan

  • Korea University Guro Hospital-Internal Medicine ( Site 2103)

    RECRUITING

    Seoul, 08308, South Korea

  • Kyung Hee University Hospital ( Site 2101)

    RECRUITING

    Seoul, 02447, South Korea

  • Kyungpook National University Chilgok Hospital-Pulmonology ( Site 2102)

    RECRUITING

    Deagu, Taegu-Kwangyokshi, 41404, South Korea

  • Lampang Cancer Hospital ( Site 2304)

    RECRUITING

    Lampang, Changwat Lampang, 52000, Thailand

  • Lotus-Med ( Site 2009)

    RECRUITING

    Bucharest, 012292, Romania

  • Mackay Memorial Hospital-Chest Medicine ( Site 2201)

    RECRUITING

    Taipei, 10449, Taiwan

  • Maharaj Nakorn Chiang Mai Hospital ( Site 2302)

    RECRUITING

    Muang, Chiang Mai, 50200, Thailand

  • Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 0800)

    RECRUITING

    Brno, Brno-mesto, 656 53, Czechia

  • Mays Cancer Center ( Site 0132)

    COMPLETED

    San Antonio, Texas, 78229, United States

  • McGill University Health Centre ( Site 0103)

    RECRUITING

    Montreal, Quebec, H4A 3J1, Canada

  • Medipol Mega Universite Hastanesi-oncology ( Site 1811)

    RECRUITING

    Stanbul, Istanbul, 34214, Turkey (Türkiye)

  • Memorial Hermann Cancer Center ( Site 0015)

    RECRUITING

    Houston, Texas, 77030, United States

  • Memorial Kayseri Hastanesi ( Site 1805)

    RECRUITING

    Kayseri, 38010, Turkey (Türkiye)

  • Mersin Sehir Eğitim ve Araştırma Hastanesi-Oncology ( Site 1808)

    RECRUITING

    Mersin, 33240, Turkey (Türkiye)

  • Mid Florida Hematology and Oncology Center ( Site 0109)

    COMPLETED

    Orange City, Florida, 32763, United States

  • Multiscan-Onkologicke a radiologicke centrum Multiscan Pardubice ( Site 0804)

    RECRUITING

    Pardubice, Pardubice Region, 532 03, Czechia

  • Nagoya University Hospital ( Site 2519)

    RECRUITING

    Nagoya, Aichi-ken, 466-8560, Japan

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier ( Site 1500)

    RECRUITING

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • National Cancer Center Hospital East ( Site 2501)

    RECRUITING

    Kashiwa, Chiba, 277-8577, Japan

  • National Center for Global Health and Medicine ( Site 2516)

    RECRUITING

    Shinjuku, Tokyo, 162-8655, Japan

  • National Cheng Kung University Hospital ( Site 2205)

    RECRUITING

    Tainan, 704, Taiwan

  • National Hospital Organization Kyushu Medical Center ( Site 2509)

    RECRUITING

    Fukuoka, 810-8563, Japan

  • National Hospital Organization Ureshino Medical Center ( Site 2524)

    RECRUITING

    Ureshino, Saga-ken, 843-0393, Japan

  • National Hospital Organization Yamaguchi Ube Medical Center ( Site 2523)

    RECRUITING

    Ube, Yamaguchi, 755-0241, Japan

  • National Taiwan University Cancer Center (NTUCC) ( Site 2209)

    RECRUITING

    Taipei City, Taipei, 106, Taiwan

  • National Taiwan University Hospital-Oncology ( Site 2208)

    RECRUITING

    Taipei, 10002, Taiwan

  • Nemocnice AGEL Ostrava - Vitkovice a.s.-Plicni oddeleni ( Site 0803)

    RECRUITING

    Ostrava-Vitkovice, Ostrava Mesto, 703 00, Czechia

  • New Mexico Oncology Hematology Consultants Ltd. ( Site 0123)

    COMPLETED

    Albuquerque, New Mexico, 87109, United States

  • Niigata Cancer Center Hospital ( Site 2505)

    RECRUITING

    Niigata, 951-8566, Japan

  • North West Cancer Centre ( Site 1908)

    RECRUITING

    Londonderry, Derry and Strabane, BT47 6SB, United Kingdom

  • Northern Jiangsu People's Hospital-General Surgery Department ( Site 2403)

    ACTIVE_NOT_RECRUITING

    Yangzhou, Jiangsu, 225001, China

  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0001)

    COMPLETED

    Marietta, Georgia, 30060, United States

  • ONCOCENTRO APYS-ACEREY ( Site 0400)

    RECRUITING

    Viña del Mar, Valparaiso, 2520598, Chile

  • Oncologos del Occidente ( Site 0504)

    RECRUITING

    Pereira, Risaralda Department, 660001, Colombia

  • Oncology Consultants P.A. ( Site 0124)

    RECRUITING

    Houston, Texas, 77030, United States

  • Oncosalud-Clinical Research ( Site 0600)

    RECRUITING

    Lima, 15036, Peru

  • Ordensklinikum Linz GmbH Elisabethinen-Department of Pneumology ( Site 0720)

    RECRUITING

    Linz, Upper Austria, 4020, Austria

  • Országos Korányi Pulmonológiai Intézet ( Site 1104)

    RECRUITING

    Budapest, 1121, Hungary

  • Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 2506)

    RECRUITING

    Osaka, 541-8567, Japan

  • Ospedale San Martino ( Site 1407)

    RECRUITING

    Genova, 16132, Italy

  • Ospedale di Circolo e Fondazione Macchi Varese-Oncology ( Site 1413)

    COMPLETED

    Varese, 21100, Italy

  • Peking Union Medical College Hospital ( Site 2412)

    ACTIVE_NOT_RECRUITING

    Beijing, Beijing Municipality, 100730, China

  • Petz Aladar Egyetemi Oktato Korhaz ( Site 1101)

    RECRUITING

    Győr, Győr-Moson-Sopron, 9024, Hungary

  • Pontificia Universidad Catolica de Chile-Hemato-Oncology ( Site 0402)

    RECRUITING

    Santiago, Region M. de Santiago, 8330024, Chile

  • Prapokklao Hospital ( Site 2306)

    RECRUITING

    Mueang, Changwat Chanthaburi, 22000, Thailand

  • Pusan National University Hospital ( Site 2100)

    RECRUITING

    Busan, Pusan-Kwangyokshi, 49241, South Korea

  • Pusan National University Yangsan Hospital ( Site 2104)

    RECRUITING

    Yangsan, Kyongsangnam-do, 50612, South Korea

  • Rabin Medical Center ( Site 1303)

    RECRUITING

    Petah Tikva, 4941492, Israel

  • Rambam Health Care Campus-Oncology Division ( Site 1302)

    COMPLETED

    Haifa, 3109601, Israel

  • Reformatus Pulmonologiai Centrum ( Site 1102)

    RECRUITING

    Törökbálint, Pest County, 2045, Hungary

  • Regionalny Szpital Specjalistyczny im. dr. Władyslawa Biegańskiego ( Site 1513)

    COMPLETED

    Grudziądz, Kuyavian-Pomeranian Voivodeship, 86-300, Poland

  • Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0122)

    RECRUITING

    Burbank, California, 91505, United States

  • SC ONCO CARD SRL ( Site 2007)

    RECRUITING

    Brasov, 500052, Romania

  • SC Radiotherapy Center Cluj SRL-Oncologie Medicala ( Site 2001)

    RECRUITING

    Florești, Cluj, 407280, Romania

  • SRH Wald-Klinikum Gera-Zentrum für klinische Studien ( Site 1006)

    RECRUITING

    Gera, Thuringia, 07548, Germany

  • Sainte Catherine Institut du Cancer Avignon Provence ( Site 0902)

    RECRUITING

    Avignon, Vaucluse, 84000, France

  • Saiseikai Matsusaka Municipal Hospital ( Site 2522)

    RECRUITING

    Matsusaka, Mie-ken, 515-8544, Japan

  • Saitama Prefectural Cancer Center ( Site 2512)

    RECRUITING

    Kitaadachi-gun, Saitama, 362-0806, Japan

  • Samsun Medical Park Hastanesi-medical oncology ( Site 1806)

    RECRUITING

    Samsun, 55200, Turkey (Türkiye)

  • Sanatorio Parque ( Site 0201)

    RECRUITING

    Rosario, Santa Fe Province, S2000DSV, Argentina

  • Sendai Kousei Hospital ( Site 2507)

    RECRUITING

    Sendai, Miyagi, 981-0914, Japan

  • Shaare Zedek Medical Center ( Site 1300)

    RECRUITING

    Jerusalem, 9103102, Israel

  • Shanghai East Hospital ( Site 2428)

    ACTIVE_NOT_RECRUITING

    Shanghai, Shanghai Municipality, 200120, China

  • Shanghai Pulmonary Hospital ( Site 2427)

    ACTIVE_NOT_RECRUITING

    Shanghai, Shanghai Municipality, 200433, China

  • Sharp Memorial Hospital ( Site 9544)

    RECRUITING

    San Diego, California, 92123, United States

  • Sheba Medical Center ( Site 1301)

    RECRUITING

    Ramat Gan, 5265601, Israel

  • Sichuan Cancer hospital. ( Site 2421)

    ACTIVE_NOT_RECRUITING

    Chengdu, Sichuan, 610042, China

  • Sir Run Run Shaw Hospital of Zhejiang University School of Medicine-Medical Oncology ( Site 2407)

    ACTIVE_NOT_RECRUITING

    Hangzhou, Zhejiang, 310016, China

  • Sociedad De Oncología y Hematología Del Cesar SAS-Oncology ( Site 0501)

    ACTIVE_NOT_RECRUITING

    Valledupar, Cesar Department, 200001, Colombia

  • Songklanagarind hospital ( Site 2303)

    RECRUITING

    Hat Yai, Changwat Songkhla, 90110, Thailand

  • Southeastern Regional Medical Center ( Site 0004)

    COMPLETED

    Newnan, Georgia, 30265, United States

  • Southern Medical University Nanfang Hospital-Depatrment of Respiratory and Critical Care Medicine ( Site 2416)

    ACTIVE_NOT_RECRUITING

    Guangzhou, Guangdong, 510515, China

  • St Bartholomew's Hospital ( Site 1901)

    RECRUITING

    London, London, City of, EC1A7BE, United Kingdom

  • St Luke's University Health Network ( Site 0017)

    RECRUITING

    Bethlehem, Pennsylvania, 18015, United States

  • St. James's Hospital ( Site 1200)

    RECRUITING

    Dublin, D08 A978, Ireland

  • St. Marianna University Hospital ( Site 2521)

    RECRUITING

    Kawasaki, Kanagawa, 216-8511, Japan

  • St. Marys Hospital Center ( Site 0105)

    RECRUITING

    Montreal, Quebec, H3T 1M5, Canada

  • Standort Penzing der Klinik Ottakring-Abteilung für Atemwegs-und Lungenkrankheiten ( Site 0730)

    RECRUITING

    Vienna, 1140, Austria

  • Szpital Specjalistyczny im. Henryka Klimontowicza ( Site 1507)

    COMPLETED

    Gorlice, Lesser Poland Voivodeship, 38-300, Poland

  • Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie-Oncology Department ( Site 1515)

    RECRUITING

    Krakow, Lesser Poland Voivodeship, 31-826, Poland

  • Szpital Wojewódzki w Koszalinie. ( Site 1517)

    RECRUITING

    Poland, West Pomeranian Voivodeship, 75-581, Poland

  • Taichung Veterans General Hospital ( Site 2204)

    RECRUITING

    Taichung, 407, Taiwan

  • Taizhou Hospital of Zhejiang Province ( Site 2430)

    ACTIVE_NOT_RECRUITING

    Taizhou, Zhejiang, 317000, China

  • Takarazuka City Hospital ( Site 2508)

    RECRUITING

    Takarazuka, Hyōgo, 665-0827, Japan

  • Taoyuan General Hospital ( Site 2203)

    RECRUITING

    Taoyuan City, Taoyuan, 33004, Taiwan

  • The Affiliated Cancer Hospital of Xinjiang Medical University ( Site 2425)

    ACTIVE_NOT_RECRUITING

    Ürümqi, Xinjiang, 830000, China

  • The Catholic University of Korea, Incheon St. Mary's Hospital ( Site 2106)

    RECRUITING

    Bupyeong-gu, Incheon, 21431, South Korea

  • The First Affiliated Hospital of Guangzhou Medical University ( Site 2417)

    ACTIVE_NOT_RECRUITING

    Guangzhou, Guangdong, 510160, China

  • The First Affiliated Hospital of Wenzhou Medical University-Respiratory department ( Site 2409)

    ACTIVE_NOT_RECRUITING

    Wenzhou, Zhejiang, 325015, China

  • The First Affiliated hospital of Xiamen University-oncology ( Site 2420)

    ACTIVE_NOT_RECRUITING

    Xiamen, Fujian, 361003, China

  • The First Hospital of Jilin University-Oncology ( Site 2414)

    ACTIVE_NOT_RECRUITING

    Changchun, Jilin, 130021, China

  • The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 2404)

    ACTIVE_NOT_RECRUITING

    Nanchang, Jiangxi, 330209, China

  • The Second Affiliated Hospital of Nanchang University-Oncology Department ( Site 2405)

    ACTIVE_NOT_RECRUITING

    Nanchang, Jiangxi, 330006, China

  • The Second Xiangya Hospital of Central South University-Oncology ( Site 2418)

    ACTIVE_NOT_RECRUITING

    Changsha, Hunan, 410011, China

  • The first Affiliated Hospital, Zhejiang University School of Medicine-Respiratory Department ( Site 2406)

    ACTIVE_NOT_RECRUITING

    Hangzhou, Zhejiang, 310000, China

  • Thomas Jefferson University - Clinical Research Institute ( Site 0147)

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

  • Toho University Omori Medical Center ( Site 2520)

    RECRUITING

    Ōta-ku, Tokyo, 143-8541, Japan

  • Tohoku University Hospital ( Site 2525)

    RECRUITING

    Sendai, Miyagi, 980-8574, Japan

  • Tongji Hospital Tongji Medical,Science & Technology ( Site 2424)

    ACTIVE_NOT_RECRUITING

    Wuhan, Hubei, 430000, China

  • Torbay Hospital ( Site 1906)

    RECRUITING

    Torquay, Devon, TQ2 7AA, United Kingdom

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor ( Site 9552)

    RECRUITING

    Ypsilanti, Michigan, 48197, United States

  • University of Chicago Medical Center ( Site 0145)

    RECRUITING

    Chicago, Illinois, 60637, United States

  • University of New Mexico Comprehensive Cancer Center ( Site 0135)

    RECRUITING

    Albuquerque, New Mexico, 87131, United States

  • Universitätsklinikum Schleswig-Holstein-Pneumologie ( Site 1000)

    RECRUITING

    Lübeck, Schleswig-Holstein, 23538, Germany

  • Uniwersytecki Szpital Kliniczny Nr 4 w Lublinie ( Site 1518)

    RECRUITING

    Lublin, Lublin Voivodeship, 20-090, Poland

  • Vencer Centro de Pesquisa Clínica ( Site 0309)

    RECRUITING

    Teresina, Piauí, 64049-200, Brazil

  • Washington Hospital Center ( Site 0037)

    RECRUITING

    Washington D.C., District of Columbia, 20010, United States

  • Waterloo Regional Health Network (WRHN) ( Site 0153)

    RECRUITING

    Kitchener, Ontario, N2G 1G3, Canada

  • West China Hospital, Sichuan University ( Site 2422)

    ACTIVE_NOT_RECRUITING

    Chengdu, Sichuan, 610041, China

  • Wielkopolskie Centrum Pulmonologii i Torakochirurgii-Oddzial Onkologii Klinicznej z Pododdzialem Dz ( Site 1510)

    RECRUITING

    Poznań, Lower Silesian Voivodeship, 60-569, Poland

  • Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1501)

    RECRUITING

    Przemyśl, Podkarpackie Voivodeship, 37-700, Poland

  • Zala Megyei Szent Rafael Kórház ( Site 1110)

    RECRUITING

    Zalaegerszeg, Zala County, 8900, Hungary

  • Zhejiang Cancer Hospital-Breast Oncology ( Site 2408)

    ACTIVE_NOT_RECRUITING

    Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.